Anti–Insulin Receptor Antibody for Malignant Insulinoma and Refractory Hypoglycemia

Anti–Insulin Receptor Antibody for Malignant Insulinoma and Refractory Hypoglycemia

This letter reports the anti–insulin receptor monoclonal antibody RZ358 as a successful treatment for severe and refractory hypoglycemia in a patient with malignant insulinoma.

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:The New England journal of medicine 2023-08, Vol.389 (8), p.767-769
Hauptverfasser: Osataphan, Soravis, Vamvini, Maria, Rosen, Evan D., Pei, Lei, Erlikh, Natanie, Singh, Gurcharan, Dhorajiya, Poojaben, Parker, J. Anthony, Dreyfuss, Jonathan M., Rattani, Ahmed, Patti, Mary-Elizabeth
Format: Artikel
Sprache:eng
Schlagworte:
Antibodies - immunology
Dehydrogenases
Diabetes
Endocrinology
Endocrinology General
Gastroenterology
Gastrointestinal Tract Cancer
Glucose
Hematology
Humans
Hypoglycemia
Hypoglycemia - etiology
Hypoglycemia - therapy
Insulin
Insulin - immunology
Insulin Antagonists - immunology
Insulin Antagonists - therapeutic use
Insulin receptors
Insulin resistance
Insulinoma
Insulinoma - complications
Insulinoma - immunology
Insulinoma - therapy
Metabolism
Metastasis
Monoclonal antibodies
Oncology
Pancreatic Neoplasms - complications
Pancreatic Neoplasms - immunology
Pancreatic Neoplasms - therapy
Peptides
Phosphates
Radiation therapy
Sensors
Treatments in Oncology
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:This letter reports the anti–insulin receptor monoclonal antibody RZ358 as a successful treatment for severe and refractory hypoglycemia in a patient with malignant insulinoma.
ISSN:0028-4793
1533-4406
DOI:10.1056/NEJMc2307576